Trastuzumab deruxtecan yields promising results in HER2-positive breast cancer patients pretreated with TDM-1
Published: 18 Dec 2019
Views: 3735
Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA
Dr Ian Krop gives a press conference at the 2019 San Antonio Breast Cancer Symposium about the latest results from the DENSITY-Breast01 study.
Watch our interview with Dr Krop here.
Read more about the study here.
Related Videos
IMPRIME 1: Combination of pembrolizumab and a novel innate immune activator, Imp...
Dr Steven O'Day - John Wayne Cancer Institute, Santa Monica, USA
19 May 2020
Immune checkpoint based approaches in AML and MDS
Dr Naval Daver - University of Texas MD Anderson Cancer Center, Houston, USA
8 Apr 2020
ASCO GU 2020: Bladder: Genomic profiling, real-world treatment challenges and no...
Dr Petros Grivas, Dr Shilpa Gupta, Dr Alison Birtle and Dr Joseph Jacob
14 Feb 2020
The new era of ALL treatment
Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain
23 Jan 2020
HER2CLIMB: Investigating tucatinib with capecitabine and trastuzumab in HER2-pos...
Dr Rashmi Murthy - MD Anderson Cancer Center, Houston, USA
23 Jan 2020
Adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for HER2-positive b...
Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA
19 Dec 2019
APHINITY: Adding pertuzumab to trastuzumab plus chemotherapy in patients with op...
Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium
18 Dec 2019
Could trastuzumab deruxtecan become the new standard of care for pretreated HER2...
Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA
18 Dec 2019
Pertuzumab plus trastuzumab and chemotherapy continues to show benefit in HER2-p...
Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium
18 Dec 2019
